{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:25:40Z","timestamp":1780496740953,"version":"3.54.1"},"reference-count":148,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Clear cell renal cell carcinoma (ccRCC) is characterized by a complex molecular landscape driven by recurrent genetic alterations. While genomic and transcriptomic profiling have identified core drivers, they often fail to provide robust biomarkers due to the significant decoupling of mRNA and protein levels, as well as the critical role of post-translational modifications in tumor biology. This review synthesizes current evidence from landmark proteogenomic initiatives, such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), and independent multi-omic studies. It evaluates the integration of genomic, transcriptomic, and proteomic data to map metabolic reprogramming, signalling pathway activity, and chromatin-level alterations in ccRCC. Proteogenomic analyses reveal that protein-level data provide a functional perspective that is missing from sequencing alone, specifically identifying suppressed oxidative phosphorylation, enhanced glycolysis, and the activation of the PI3K\/AKT\/mTOR cascade, independent of genetic mutations. Furthermore, proteogenomics has defined novel molecular subtypes and individual protein biomarkers, such as UCHL1 and p-mTOR, which correlate more accurately with clinical outcomes and therapeutic responses than their transcriptomic counterparts. Proteogenomics is a crucial tool for refining disease taxonomy and identifying novel therapeutic vulnerabilities in ccRCC. By bridging the gap between genotype and functional phenotype, this integrated approach facilitates more precise risk stratification and accelerates the development of personalized medicine through better-informed selection of targeted and immune-based therapies.<\/jats:p>","DOI":"10.3390\/ijms27115054","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:46:48Z","timestamp":1780494408000},"page":"5054","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From Genes to Proteins: The Indispensable Role of Proteogenomics in Advancing Clear Cell Renal Cell Carcinoma Research"],"prefix":"10.3390","volume":"27","author":[{"given":"Filip","family":"Kasperczak","sequence":"first","affiliation":[{"name":"Department of Urology, J. Stru\u015b Hospital in Pozna\u0144, Szwajcarska 3, 61-285 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Paw\u0142owska-Kasperczak","sequence":"additional","affiliation":[{"name":"Department of Urology, J. Stru\u015b Hospital in Pozna\u0144, Szwajcarska 3, 61-285 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Szu\u015bcik","sequence":"additional","affiliation":[{"name":"Department of Urology, J. Stru\u015b Hospital in Pozna\u0144, Szwajcarska 3, 61-285 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Zysnarska","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences, Prince Mieszko I Poznan Medical University of Applied Sciences, 60-320 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Rajwa","sequence":"additional","affiliation":[{"name":"Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Second Department of Urology, Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland"},{"name":"Division of Surgery and Interventional Science, University College London, London NW3 2PS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7410-0712","authenticated-orcid":false,"given":"Takafumi","family":"Yanagisawa","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine, Tokyo 105-8461, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4178-373X","authenticated-orcid":false,"given":"Fabio","family":"Zattoni","sequence":"additional","affiliation":[{"name":"Department of Surgery, Oncology, and Gastroenterology, Urology Clinic, University of Padua, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8396-3045","authenticated-orcid":false,"given":"Micha\u0142","family":"Kasperczak","sequence":"additional","affiliation":[{"name":"Department of Urology, J. Stru\u015b Hospital in Pozna\u0144, Szwajcarska 3, 61-285 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"ref_1","unstructured":"International Agency for Research on Cancer (2024). GLOBOCAN 2022: Kidney Fact Sheet, IARC. Available online: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/29-kidney-fact-sheet.pdf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","article-title":"The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs\u2014Part A: Renal, Penile, and Testicular Tumours","volume":"82","author":"Moch","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Vento, J., Zhang, T., Kapur, P., Hammers, H., Brugarolas, J., and Qin, Q. (2025). Systemic Treatment of Locally Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma. Cancers, 17.","DOI":"10.3390\/cancers17091527"},{"key":"ref_4","unstructured":"WHO Classification of Tumours Editorial Board (2022). WHO Classification of Tumours: Urinary System and Male Genital Organs, International Agency for Research on Cancer. [5th ed.]."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e8967","DOI":"10.1002\/ccr3.8967","article-title":"Metastasectomy for extracalvarial renal cell carcinoma","volume":"12","author":"Kasem","year":"2024","journal-title":"Clin. Case Rep."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Quinn, A.E., Bell, S.D., Marrah, A.J., Wakefield, M.R., and Fang, Y. (2024). The Current State of the Diagnoses and Treatments for Clear Cell Renal Cell Carcinoma. Cancers, 16.","DOI":"10.3390\/cancers16234034"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ccell.2022.12.001","article-title":"Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness","volume":"41","author":"Li","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1470-2045(12)70584-3","article-title":"Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: A retrospective analysis with independent validation","volume":"14","author":"Kapur","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.eururo.2023.04.003","article-title":"Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma","volume":"84","author":"Cotta","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12014-020-09291-w","article-title":"Proteomic approaches for characterizing renal cell carcinoma","volume":"17","author":"Clark","year":"2020","journal-title":"Clin. Proteom."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1038\/s41467-022-30342-3","article-title":"Proteogenomic characterization of 2002 human cancers reveals pan-cancer molecular subtypes and associated pathways","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.cell.2019.10.007","article-title":"Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma","volume":"179","author":"Clark","year":"2019","journal-title":"Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12935-025-03944-2","article-title":"Integration of multi-omics approaches in exploring intra-tumoral heterogeneity","volume":"25","author":"Dong","year":"2025","journal-title":"Cancer Cell Int."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Huang, J., Cai, W., Cai, B., Kong, W., Zhai, W., Zhang, J., Chen, Y., Chen, S., Bai, Y., and Huang, Y. (2021). Comprehensive Genomic Landscape in Chinese Clear Cell Renal Cell Carcinoma Patients. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.697219"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12935-018-0661-5","article-title":"Somatic mutations in renal cell carcinomas from Chinese patients revealed by whole exome sequencing","volume":"18","author":"Wang","year":"2018","journal-title":"Cancer Cell Int."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41392-023-01362-2","article-title":"Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma","volume":"8","author":"Hu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/path.5022","article-title":"Genomic classifications of renal cell carcinoma: A critical step towards the future application of personalized kidney cancer care with pan-omics precision","volume":"244","author":"Hsieh","year":"2018","journal-title":"J. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e14536","DOI":"10.1200\/JCO.2022.40.16_suppl.e14536","article-title":"Pan-cancer analysis of PBRM1 mutation and their association with immune-related biomarkers and prognosis","volume":"40","author":"He","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/gcc.22116","article-title":"Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma","volume":"53","author":"Gossage","year":"2013","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/modpathol.2015.123","article-title":"Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death","volume":"29","author":"Ho","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/ng.2891","article-title":"Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing","volume":"46","author":"Gerlinger","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1158\/0008-5472.CAN-21-2318","article-title":"Intratumoral Resolution of Driver Gene Mutation Heterogeneity in Renal Cancer Using Deep Learning","volume":"82","author":"Acosta","year":"2022","journal-title":"Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1073\/pnas.1619726114","article-title":"Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL \u2212\/\u2212 clear cell renal carcinoma","volume":"114","author":"Gao","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"9276","DOI":"10.3390\/curroncol30100670","article-title":"Genomic Profiling and Molecular Characterization of Clear Cell Renal Cell Carcinoma","volume":"30","author":"Pezzicoli","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nature09639","article-title":"Exome sequencing identifies frequent mutation of the SWI\/SNF complex gene PBRM1 in renal carcinoma","volume":"469","author":"Varela","year":"2011","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejca.2022.12.011","article-title":"The road to systemic therapy in von Hippel-Lindau (VHL) disease: Are we there yet?","volume":"182","author":"Shepherd","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_27","first-page":"394.e9","article-title":"Investigating the association of VHL gene variants with disease risk and clinicopathological outcomes in ccRCC patients from West Bengal, India","volume":"43","author":"Chatterjee","year":"2025","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Dai, J., Cui, Y., Liang, X., Xu, J., Li, J., Chen, Y., Zhang, E., and Guo, R. (2023). PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers. Front. Genet., 13.","DOI":"10.3389\/fgene.2022.1066347"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s12672-025-02228-5","article-title":"Molecular landscape of clear cell renal cell carcinoma: Targeting the Wnt\/\u03b2-catenin signaling pathway","volume":"16","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Greco, F., D\u2019andrea, V., Buoso, A., Cea, L., Bernetti, C., Zobel, B.B., and Mallio, C.A. (2024). Advancements in Radiogenomics for Clear Cell Renal Cell Carcinoma: Understanding the Impact of BAP1 Mutation. J. Clin. Med., 13.","DOI":"10.3390\/jcm13133960"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/s41467-022-29577-x","article-title":"A proteogenomic analysis of clear cell renal cell carcinoma in a Chinese population","volume":"13","author":"Qu","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/cas.15170","article-title":"Risk prediction for metastasis of clear cell renal cell carcinoma using digital multiplex ligation-dependent probe amplification","volume":"113","author":"Yoshikawa","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Fernandes, F.G., Silveira, H.C.S., J\u00fanior, J.N.A., da Silveira, R.A., Zucca, L.E., C\u00e1rcano, F.M., Sanches, A.O.N., Neder, L., Scapulatempo-Neto, C., and Serrano, S.V. (2021). Somatic Copy Number Alterations and Associated Genes in Clear-Cell Renal-Cell Carcinoma in Brazilian Patients. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052265"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Bolck, H.A., Migh, E., Kriston, A., Zajac, N., Kreutzer, S., Totu, T., Leary, P., Kovacs, F., Rutishauser, D., and Pfammatter, S. (2025). Deep visual multi-omics profiling reveals mechanisms that underlie cancer cell differentiation and aggressiveness in clear cell renal cell carcinoma. bioRxiv.","DOI":"10.1101\/2025.01.31.635927"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1038\/s41467-023-39981-6","article-title":"Proteogenomics of clear cell renal cell carcinoma response to tyrosine kinase inhibitor","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"100587","DOI":"10.1016\/j.mcpro.2023.100587","article-title":"Functional Impact of Protein\u2013RNA Variation in Clinical Cancer Analyses","volume":"22","author":"Arad","year":"2023","journal-title":"Mol. Cell. Proteom."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.ccell.2023.06.009","article-title":"Proteogenomic data and resources for pan-cancer analysis","volume":"41","author":"Li","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1158\/1078-0432.CCR-14-1993","article-title":"Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial","volume":"21","author":"Choueiri","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1158\/1078-0432.CCR-22-0923","article-title":"Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma","volume":"28","author":"Denize","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1172\/JCI67230","article-title":"HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations","volume":"123","author":"Semenza","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Ene, C.D., Penescu, M.N., Georgescu, S.R., Tampa, M., and Nicolae, I. (2020). Posttranslational Modifications Pattern in Clear Cell Renal Cell Carcinoma. Metabolites, 11.","DOI":"10.3390\/metabo11010010"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s12672-025-02737-3","article-title":"Proteomics and succinylation modification characterization in clear cell renal cell carcinoma","volume":"16","author":"Yue","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Zhu, H., Wang, X., Lu, S., and Ou, K. (2023). Metabolic reprogramming of clear cell renal cell carcinoma. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1195500"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e27374","DOI":"10.1097\/MD.0000000000027374","article-title":"Identification and validation of a hypoxia-related prognostic signature in clear cell renal cell carcinoma patients","volume":"100","author":"Li","year":"2021","journal-title":"Medicine"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ccell.2015.12.004","article-title":"An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma","volume":"29","author":"Hakimi","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40170-021-00271-8","article-title":"ASS1 and ASL suppress growth in clear cell renal cell carcinoma via altered nitrogen metabolism","volume":"9","author":"Khare","year":"2021","journal-title":"Cancer Metab."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s12672-024-01543-7","article-title":"Developing hypoxia and lactate metabolism-related molecular subtypes and prognostic signature for clear cell renal cell carcinoma through integrating machine learning","volume":"15","author":"Liu","year":"2024","journal-title":"Discov. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Badoiu, S.C., Greabu, M., Miricescu, D., Stanescu-Spinu, I.-I., Ilinca, R., Balan, D.G., Balcangiu-Stroescu, A.-E., Mihai, D.-A., Vacaroiu, I.A., and Stefani, C. (2023). PI3K\/AKT\/mTOR Dysregulation and Reprogramming Metabolic Pathways in Renal Cancer: Crosstalk with the VHL\/HIF Axis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24098391"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e11901","DOI":"10.7717\/peerj.11901","article-title":"Prognostic significance and tumor-immune infiltration of mTOR in clear cell renal cell carcinoma","volume":"9","author":"Li","year":"2021","journal-title":"PeerJ"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.eururo.2015.08.007","article-title":"Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer","volume":"69","author":"Grampp","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1200\/JCO.2012.45.2003","article-title":"Molecular genetics of clear-cell renal cell carcinoma","volume":"32","author":"Brugarolas","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1007\/s00345-018-2429-x","article-title":"Genomics and clinical correlates of renal cell carcinoma","volume":"36","author":"Mitchell","year":"2018","journal-title":"World J. Urol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1158\/1078-0432.CCR-15-2631","article-title":"Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma","volume":"22","author":"Kwiatkowski","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/ncb2763","article-title":"Signal integration by mTORC1 coordinates nutrient input with biosynthetic output","volume":"15","author":"Dibble","year":"2013","journal-title":"Nat. Cell Biol."},{"key":"ref_55","first-page":"1435","article-title":"PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma","volume":"146","author":"Beuselinck","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e3562","DOI":"10.1002\/jgm.3562","article-title":"Hsa_circ_0003596 enhances the development of cell renal clear cell carcinoma through the miR-502-5p\/IGF1\/PI3K\/AKT axis","volume":"25","author":"Fang","year":"2023","journal-title":"J. Gene Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/onc.2015.221","article-title":"High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma","volume":"35","author":"Ho","year":"2015","journal-title":"Oncogene"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s43556-024-00220-z","article-title":"Proteogenomics identifies c-Met inhibition as a therapeutic strategy for BAP1-deficient clear cell renal cell carcinoma","volume":"5","author":"Du","year":"2024","journal-title":"Mol. Biomed."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/ng.2323","article-title":"BAP1 loss defines a new class of renal cell carcinoma","volume":"44","author":"Liao","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000529861","article-title":"Clear Cell Renal Cell Carcinoma: A Comprehensive in silico Study in Searching for Therapeutic Targets","volume":"48","author":"Naghdibadi","year":"2023","journal-title":"Kidney Blood Press. Res."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Panwoon, C., Seubwai, W., Thanee, M., and Sangkhamanon, S. (2024). Identification of novel biomarkers to distinguish clear cell and non-clear cell renal cell carcinoma using bioinformatics and machine learning. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0305252"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1016\/j.csbj.2023.04.015","article-title":"A five-protein prognostic signature with GBP2 functioning in immune cell infiltration of clear cell renal cell carcinoma","volume":"21","author":"Meng","year":"2023","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Berezowski, B., Boothe, R., Chaplin, B., Del Vecchio, S.J., Fares, Z., Humphries, T.L.R., Ng, K.L., Noonan, T., Samaratunga, H., and Urquhart, A. (2025). Biomarkers in Renal Cell Carcinoma: A Systematic Review and Immunohistochemical Validation Study. Cancers, 17.","DOI":"10.3390\/cancers17152588"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"101987","DOI":"10.1016\/j.tranon.2024.101987","article-title":"Deubiquitinase UCHL1 stabilizes KDM4B to augment VEGF signaling and confer bevacizumab resistance in clear cell renal cell carcinoma","volume":"45","author":"Cheng","year":"2024","journal-title":"Transl. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Kasperczak, M., Bromi\u0144ski, G., Ko\u0142odziejczak-Guglas, I., Antczak, A., and Wiznerowicz, M. (2024). Prognostic Significance of Elevated UCHL1, SNRNP200, and PAK4 Expression in High-Grade Clear Cell Renal Cell Carcinoma: Insights from LC-MS\/MS Analysis and Immunohistochemical Validation. Cancers, 16.","DOI":"10.3390\/cancers16162844"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.juro.2008.02.044","article-title":"CpG Hypermethylation of the UCHL1 Gene Promoter is Associated With Pathogenesis and Poor Prognosis in Renal Cell Carcinoma","volume":"180","author":"Kagara","year":"2008","journal-title":"J. Urol."},{"key":"ref_67","first-page":"205.e13","article-title":"p21-Activated kinase 4 predicts early recurrence and poor survival in patients with nonmetastatic clear cell renal cell carcinoma","volume":"33","author":"Liu","year":"2015","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Kasperczak, M., Ko\u0142odziejczak-Guglas, I., Paw\u0142owska-Kasperczak, K., Wiznerowicz, M., and Antczak, A. (2025). Immunohistological Examination of HEATR1 and SLC27A2 Expression in ccRCC Samples to Evaluate Their Potential as Prognostic Markers\u2014A Preliminary Study. Cancers, 17.","DOI":"10.3390\/cancers17132234"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41420-022-01145-8","article-title":"Up-regulation of SLC27A2 suppresses the proliferation and invasion of renal cancer by down-regulating CDK3-mediated EMT","volume":"8","author":"Xu","year":"2022","journal-title":"Cell Death Discov."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Kasperczak, M., Ko\u0142odziejczak-Guglas, I., Kasperczak, F., Wiznerowicz, M., and Antczak, A. (2025). PROM1 and EFTUD2 Expression in High-Grade Clear Cell Renal Cell Carcinoma as a Molecular Marker for Survival Rate. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26136296"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1007\/s00432-012-1237-8","article-title":"CD133 expression in renal cell carcinoma (RCC) is correlated with nuclear hypoxia-inducing factor 1\u03b1 (HIF-1\u03b1)","volume":"138","author":"Sun","year":"2012","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"eaau5240","DOI":"10.1126\/sciadv.aau5240","article-title":"Pharmacological inhibition of \u03b2-catenin\/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells","volume":"5","author":"Feng","year":"2019","journal-title":"Sci. Adv."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Kasperczak, M., Ko\u0142odziejczak-Guglas, I., Kasperczak, F., Wiznerowicz, M., and Antczak, A. (2025). Prognostic Significance of Overexpression of BCL9 and TPX2 in High-Grade Clear Cell Renal Cell Carcinoma: Prognostic Markers for Metastasis and Survival. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26094114"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"21253","DOI":"10.1038\/s41598-025-05697-4","article-title":"Evaluation of the diagnostic concordance of FDA-approved PD-L1 assays in clear cell renal cell carcinoma","volume":"15","author":"Koh","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00261-020-02613-4","article-title":"Renal biopsies performed before versus during ablation of T1 renal tumors: Implications for prevention of overtreatment and follow-up","volume":"46","author":"Widdershoven","year":"2020","journal-title":"Abdom. Imaging"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Miron, B., Xu, D., and Zibelman, M. (2020). Biomarker Development for Metastatic Renal Cell Carcinoma: Omics, Antigens, T-cells, and Beyond. J. Pers. Med., 10.","DOI":"10.3390\/jpm10040225"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.2217\/fon-2020-1020","article-title":"Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: The STAR-TOR registry","volume":"17","author":"Strauss","year":"2021","journal-title":"Future Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"112409","DOI":"10.1016\/j.celrep.2023.112409","article-title":"Integrated glycoproteomic characterization of clear cell renal cell carcinoma","volume":"42","author":"Lih","year":"2023","journal-title":"Cell Rep."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Azuaje, F., Kim, S.-Y., Hernandez, D.P., and Dittmar, G. (2019). Connecting Histopathology Imaging and Proteomics in Kidney Cancer through Machine Learning. J. Clin. Med., 8.","DOI":"10.1101\/756288"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e10578","DOI":"10.1016\/j.heliyon.2022.e10578","article-title":"Machine learning-based prognosis signature for survival prediction of patients with clear cell renal cell carcinoma","volume":"8","author":"Chen","year":"2022","journal-title":"Heliyon"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Qiu, Z., Zhang, D., Garcia-Marques, F.J., Bermudez, A., Zhao, H., Peehl, D.M., Pitteri, S.J., and Brooks, J.D. (2025). Identification of Molecular Subtypes of Clear-Cell Renal Cell Carcinoma in Patient-Derived Xenografts Using Multi-Omics. Cancers, 17.","DOI":"10.3390\/cancers17081361"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"111180","DOI":"10.1016\/j.celrep.2022.111180","article-title":"Multiregional single-cell proteogenomic analysis of ccRCC reveals cytokine drivers of intratumor spatial heterogeneity","volume":"40","author":"Miheecheva","year":"2022","journal-title":"Cell Rep."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"101214","DOI":"10.1016\/j.neo.2025.101214","article-title":"Proteomic characterization of the pseudocapsule of clear cell renal cell carcinoma in VHL disease reveals a distinct microenvironment at the tumor boundary zone","volume":"68","author":"Feilen","year":"2025","journal-title":"Neoplasia"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"112198","DOI":"10.1016\/j.isci.2025.112198","article-title":"Versatile roles of annexin A4 in clear cell renal cell carcinoma: Impact on membrane repair, transcriptional signatures, and composition of the tumor microenvironment","volume":"28","author":"Wess","year":"2025","journal-title":"iScience"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2313906","article-title":"Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma","volume":"391","author":"Choueiri","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41588-024-01662-5","article-title":"Multi-omic profiling of clear cell renal cell carcinoma identifies metabolic reprogramming associated with disease progression","volume":"56","author":"Hu","year":"2024","journal-title":"Nat. Genet."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/iju.70091","article-title":"Translational Research Bridging Basic and Clinical Insights in Renal Cell Carcinoma: A Collaborative Review and Future Directions","volume":"32","author":"Jikuya","year":"2025","journal-title":"Int. J. Urol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_91","first-page":"2116","article-title":"PBRM1 and KDM5C cooperate to define high-angiogenesis tumors and increased antiangiogenic response in renal cancer","volume":"13","author":"Santos","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1007\/s00262-023-03424-4","article-title":"BAP1-related signature predicts benefits from immunotherapy over VEGFR\/mTOR inhibitors in ccRCC: A retrospective analysis of JAVELIN Renal 101 and checkmate-009\/010\/025 trials","volume":"72","author":"Liu","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Miranda-Poma, J., Trilla-Fuertes, L., L\u00f3pez-Vacas, R., L\u00f3pez-Camacho, E., Garc\u00eda-Fern\u00e1ndez, E., Pertejo, A., Lumbreras-Herrera, M.I., Zapater-Moros, A., D\u00edaz-Almir\u00f3n, M., and Dittmann, A. (2023). Proteomics Characterization of Clear Cell Renal Cell Carcinoma. J. Clin. Med., 12.","DOI":"10.3390\/jcm12010384"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1373\/clinchem.2009.136333","article-title":"Sweetening the Pot: Adding Glycosylation to the Biomarker Discovery Equation","volume":"56","author":"Drake","year":"2010","journal-title":"Clin. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Chen, L., and Kashina, A. (2021). Post-translational Modifications of the Protein Termini. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.719590"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","author":"Creighton","year":"2013","journal-title":"Nature"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.semcancer.2018.06.004","article-title":"Challenges and opportunities in the proteomic characterization of clear cell renal cell carcinoma (ccRCC): A critical step towards the personalized care of renal cancers","volume":"55","author":"Li","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Chu, G., Xu, T., Zhu, G., Liu, S., Niu, H., and Zhang, M. (2021). Identification of a Novel Protein-Based Signature to Improve Prognosis Prediction in Renal Clear Cell Carcinoma. Front. Mol. Biosci., 8.","DOI":"10.3389\/fmolb.2021.623120"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Kase, A.M., George, D.J., and Ramalingam, S. (2023). Clear Cell Renal Cell Carcinoma: From Biology to Treatment. Cancers, 15.","DOI":"10.3390\/cancers15030665"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/ki.2009.296","article-title":"The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy","volume":"76","author":"Clark","year":"2009","journal-title":"Kidney Int."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1200\/JCO.2008.16.9847","article-title":"Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206","volume":"26","author":"Rini","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"14827","DOI":"10.1038\/s41598-021-94132-5","article-title":"VHL suppresses RAPTOR and inhibits mTORC1 signaling in clear cell renal cell carcinoma","volume":"11","author":"Ganner","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2016.10.007","article-title":"Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma","volume":"71","author":"Hsieh","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.aan5951","article-title":"Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma","volume":"359","author":"Miao","year":"2018","journal-title":"Science"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1001\/jamaoncol.2019.3158","article-title":"Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma","volume":"5","author":"Braun","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1038\/s41467-020-15959-6","article-title":"PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma","volume":"11","author":"Liu","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/s41591-020-1044-8","article-title":"Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: Biomarker analysis of the phase 3 JAVELIN Renal 101 trial","volume":"26","author":"Motzer","year":"2020","journal-title":"Nat. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","article-title":"Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade","volume":"38","author":"Motzer","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41591-020-0839-y","article-title":"Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma","volume":"26","author":"Braun","year":"2020","journal-title":"Nat. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"13373","DOI":"10.1073\/pnas.1404848111","article-title":"Direct regulation of GAS6\/AXL signaling by HIF promotes renal metastasis through SRC and MET","volume":"111","author":"Rankin","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1038\/onc.2015.343","article-title":"Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma","volume":"35","author":"Zhou","year":"2016","journal-title":"Oncogene"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Senturk, A., Sahin, A.T., Armutlu, A., Kiremit, M.C., Acar, O., Erdem, S., Bagbudar, S., Esen, T., Tuncbag, N., and Ozlu, N. (2021). Quantitative proteomics identifies secreted diagnostic biomarkers as well as tumor-dependent prognostic targets for clear cell Renal Cell Carcinoma. bioRxiv.","DOI":"10.1101\/2021.02.08.430238"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"592","DOI":"10.21873\/cgp.20408","article-title":"Using Comparative Proteomics to Identify Protein Signatures in Clear Cell Renal Cell Carcinoma","volume":"20","author":"Park","year":"2023","journal-title":"Cancer Genom. Proteom."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Piana, D., Iavarone, F., De Paolis, E., Daniele, G., Parisella, F., Minucci, A., Greco, V., and Urbani, A. (2024). Phenotyping Tumor Heterogeneity through Proteogenomics: Study Models and Challenges. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25168830"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3109\/08860220903100713","article-title":"Challenges of genomics and proteomics in nephrology","volume":"31","author":"Stojnev","year":"2009","journal-title":"Ren. Fail."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.3390\/cimb46050279","article-title":"Proteogenomics in Nephrology: A New Frontier in Nephrological Research","volume":"46","author":"Chavali","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1681\/ASN.2006090956","article-title":"Advances in urinary proteome analysis and biomarker discovery","volume":"18","author":"Fliser","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"7143","DOI":"10.1093\/nar\/gkad519","article-title":"A critical spotlight on the paradigms of FFPE-DNA sequencing","volume":"51","author":"Steiert","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/pmic.201100550","article-title":"Toward deciphering proteomes of formalin-fixed paraffin-embedded (FFPE) tissues","volume":"12","author":"Magdeldin","year":"2012","journal-title":"Proteomics"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1007\/s13361-017-1706-z","article-title":"Quantitative Proteomic Analysis of Optimal Cutting Temperature (OCT) Embedded Core-Needle Biopsy of Lung Cancer","volume":"28","author":"Zhao","year":"2017","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41591-020-0844-1","article-title":"A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors","volume":"26","author":"Slyper","year":"2020","journal-title":"Nat. Med."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Lattanzi, W., Ripoli, C., Greco, V., Barba, M., Iavarone, F., Minucci, A., Urbani, A., Grassi, C., and Parolini, O. (2021). Basic and preclinical research for personalized medicine. J. Pers. Med., 11.","DOI":"10.3390\/jpm11050354"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"101097","DOI":"10.1016\/j.mam.2022.101097","article-title":"Pathological implication of protein post-translational modifications in cancer","volume":"86","author":"Pan","year":"2022","journal-title":"Mol. Asp. Med."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Kwon, Y.W., Jo, H.-S., Bae, S., Seo, Y., Song, P., Song, M., and Yoon, J.H. (2021). Application of Proteomics in Cancer: Recent Trends and Approaches for Biomarkers Discovery. Front. Med., 8.","DOI":"10.3389\/fmed.2021.747333"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41576-020-0258-4","article-title":"mRNAs, proteins and the emerging principles of gene expression control","volume":"21","author":"Buccitelli","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s42003-021-02142-w","article-title":"A combined approach for single-cell mRNA and intracellular protein expression analysis","volume":"4","author":"Tarbier","year":"2021","journal-title":"Commun. Biol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nrg3185","article-title":"Insights into the regulation of protein abundance from proteomic and transcriptomic analyses","volume":"13","author":"Vogel","year":"2012","journal-title":"Nat. Rev. Genet."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41587-019-0037-y","article-title":"Multi-omic measurements of heterogeneity in HeLa cells across laboratories","volume":"37","author":"Liu","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1586\/14789450.4.1.39","article-title":"Urinary proteomics: A tool to discover biomarkers of kidney diseases","volume":"4","author":"Dihazi","year":"2007","journal-title":"Expert Rev. Proteom."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/nprot.2017.040","article-title":"Quantitative proteomics: Challenges and opportunities in basic and applied research","volume":"12","author":"Schubert","year":"2017","journal-title":"Nat. Protoc."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/jcp.47.7.585","article-title":"Method for assessment of laboratory turnaround times: Comparison before, during, and after analysis","volume":"47","author":"Smellie","year":"1994","journal-title":"J. Clin. Pathol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1586\/14789450.2014.976558","article-title":"Targeted proteomics: A bridge between discovery and validation","volume":"11","author":"Harlan","year":"2014","journal-title":"Expert Rev. Proteom."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12014-025-09567-z","article-title":"Mass spectrometry-based proteomics of FFPE tissues: Progress, limitations, and clinical translation barriers","volume":"22","author":"AlHammadi","year":"2025","journal-title":"Clin. Proteom."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"nwaf278","DOI":"10.1093\/nsr\/nwaf278","article-title":"The coming era of proteomics-driven precision medicine","volume":"12","author":"Jiang","year":"2025","journal-title":"Natl. Sci. Rev."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11934-025-01276-2","article-title":"Multiomics in Renal Cell Carcinoma: Current Landscape and Future Directions for Precision Medicine","volume":"26","author":"Gavi","year":"2025","journal-title":"Curr. Urol. Rep."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-Lemus, E., and Ochoa, S. (2024). Methods for multi-omic data integration in cancer research. Front. Genet., 15.","DOI":"10.3389\/fgene.2024.1425456"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.2025.43.5_suppl.588","article-title":"Use of integrated multi-omics profiling in renal cell carcinoma to identify molecular subtypes and associated clinical outcomes and therapeutic vulnerabilities","volume":"43","author":"Kim","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cell.2018.04.008","article-title":"Revolutionizing Precision Oncology through Collaborative Proteogenomics and Data Sharing","volume":"173","author":"Rodriguez","year":"2018","journal-title":"Cell"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Terrematte, P., Andrade, D.S., Justino, J., Stransky, B., de Ara\u00fajo, D.S.A., and Neto, A.D.D. (2022). A Novel Machine Learning 13-Gene Signature: Improving Risk Analysis and Survival Prediction for Clear Cell Renal Cell Carcinoma Patients. Cancers, 14.","DOI":"10.3390\/cancers14092111"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41581-019-0233-5","article-title":"Proteomic signatures of clear cell renal cell carcinoma","volume":"16","author":"Creighton","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"418","DOI":"10.18632\/oncotarget.6225","article-title":"The ribosomal protein S6 in renal cell carcinoma: Functional relevance and potential as biomarker","volume":"7","author":"Knoll","year":"2015","journal-title":"Oncotarget"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/PPO.0b013e3182a102d1","article-title":"PBRM1 and BAP1 as novel targets for renal cell carcinoma","volume":"19","author":"Brugarolas","year":"2013","journal-title":"Cancer J."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.juro.2015.07.113","article-title":"Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression","volume":"195","author":"Joseph","year":"2016","journal-title":"J. Urol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e883","DOI":"10.1002\/ctm2.883","article-title":"Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma","volume":"12","author":"Reustle","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Berkovska, O., Schliemann, I., Mermelekas, G., \u00d6zkan, N.E., Nikpour, M., Haakensen, V.D., Helland, \u00c5., Lehti\u00f6, J., and Orre, L.M. (2026). Mass spectrometry-based proteomics delivers in-depth proteome profiling of FFPE lung cancer biopsies from single glass slides. bioRxiv.","DOI":"10.64898\/2026.01.20.700495"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1200\/JCO.2024.42.16_suppl.4506","article-title":"Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell carcinoma (RCC) at increased risk of recurrence after resection","volume":"42","author":"Albiges","year":"2024","journal-title":"J. Clin. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/11\/5054\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:51:46Z","timestamp":1780494706000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/11\/5054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":148,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["ijms27115054"],"URL":"https:\/\/doi.org\/10.3390\/ijms27115054","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]}}}